Review
Medical Laboratory Technology
Sita Awasthi, Harvey M. Friedman
Summary: The rapid development of two nucleoside-modified mRNA vaccines has revolutionized the field of COVID-19 vaccines with their safety and high effectiveness. The mRNA technology offers advantages such as accelerated immunogen discovery, robust immune response induction, and rapid manufacturing scale-up. Developing a genital herpes vaccine has been a longstanding public health priority, and the advent of mRNA technology holds promise in changing the narrative. The development of nucleoside-modified mRNA-lipid nanoparticle vaccines for genital herpes shows great potential in inducing higher levels of neutralizing antibodies and more durable immune responses compared to protein-adjuvanted vaccines.
TRANSLATIONAL RESEARCH
(2022)
Review
Immunology
Madalina Preda, Loredana Sabina Cornelia Manolescu, Razvan Daniel Chivu
Summary: Alpha herpes simplex viruses pose a significant public health problem, affecting people of all ages. From common cold sores to severe conditions like encephalitis and newborn mortality, the virus produces varying levels of pathology. While there is an efficient vaccine for varicella-zoster virus, there is no available vaccine for herpes simplex virus 1 and 2 despite several approaches, including trivalent subunit vaccines and bioinformatic studies. However, recent promising attempts, such as a trivalent vaccine and a multivalent DNA vaccine, offer hope for future solutions.
Article
Immunology
Jonathan D. Joyce, Anant K. Patel, Brandie Murphy, Daniel J. J. Carr, Edward Gershburg, Andrea S. Bertke
Summary: The study showed that the two novel live-attenuated HSV-2 vaccine candidates are safe in guinea pigs and do not establish latency in neural ganglia. In contrast, wild-type HSV-2 resulted in acute disease and latent infection in neural ganglia. Both vaccine candidates elicited neutralizing antibodies.
Article
Medicine, General & Internal
Jack Stone, Katharine Jane Looker, Romain Silhol, Katherine Mary Elizabeth Turner, Richard Hayes, Jenny Coetzee, Stefan Baral, Sheree Schwartz, Philippe Mayaud, Sami Gottlieb, Marie-Claude Boily, Peter Vickerman
Summary: HSV-2 vaccination in South Africa can significantly reduce the prevalence of HSV-2 and HIV. A prophylactic vaccine with 80% efficacy can reduce HSV-2 incidence by 84.1% and HIV incidence by 65.4%. A therapeutic vaccine with 80% efficacy can reduce HSV-2 incidence by 29.6% and HIV incidence by 26.4%.
Article
Virology
Mingming Wan, Xiao Yang, Jie Sun, Xue Ding, Zhijun Chen, Weiheng Su, Linjun Cai, Ali Hou, Bo Sun, Feng Gao, Chunlai Jiang, Yan Zhou
Summary: This study evaluated three recombinant vaccines as therapeutic vaccines against acute and recurrent genital herpes. The rAd-gD2 Delta UL25 vaccine induced a higher titer of binding antibody, while the rAd-gD2 + rAd-Delta UL25 vaccine induced a higher titer of neutralizing antibody. Both vaccines significantly improved survival rates and reduced viral replication.
Article
Immunology
Robert B. Belshe, Tamara P. Blevins, Yinyi Yu, Amanda E. Nethington, Abbie Bellamy, Christopher Bryant, Lynda A. Morrison
Summary: The study found that the use of the gD2 vaccine can induce neutralizing antibodies that are associated with protection against herpes simplex virus 1 (HSV) disease, but do not offer significant protection against HSV 2 disease.
JOURNAL OF INFECTIOUS DISEASES
(2023)
Article
Medicine, Research & Experimental
Sita Awasthi, James J. Knox, Angela Desmond, Mohamad-Gabriel Alameh, Brian T. Gaudette, John M. Lubinski, Alexis Naughton, Lauren M. Hook, Kevin P. Egan, Ying K. Tam, Norbert Pardi, David Allman, Eline T. Luning Prak, Michael P. Cancro, Drew Weissman, Gary H. Cohen, Harvey M. Friedman
Summary: Nucleoside-modified mRNA vaccines show more durable protection in animal models compared to protein vaccines, with higher neutralizing antibody titers and robust B cell immune memory. The correlation between high neutralizing titers and B cell immune memory likely explains the more lasting protection provided by the mRNA vaccine.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Virology
Gheyath K. K. Nasrallah, Soha R. R. Dargham, Duaa W. W. Al-Sadeq, Fathima H. H. Amanullah, Farah M. M. Shurrab, Parveen B. B. Nizamuddin, Hiam Chemaitelly, Houssein H. H. Ayoub, Sami Abdeen, Ashraf Abdelkarim, Faisal Daraan, Ahmed Ismail, Nahid Mostafa, Mohamed Sahl, Jinan Suliman, Elias Tayar, Hasan Ali Kasem, Meynard J. A. Agsalog, Bassam K. Akkarathodiyil, Ayat A. Alkhalaf, Mohamed Morhaf M. H. Alakshar, Abdulsalam Ali A. H. Al-Qahtani, Monther H. A. Al-Shedifat, Anas Ansari, Ahmad Ali Ataalla, Sandeep Chougule, Abhilash K. K. V. Gopinathan, Feroz J. J. Poolakundan, Sanjay U. U. Ranbhise, Saed M. A. Saefan, Mohamed M. M. Thaivalappil, Abubacker S. S. Thoyalil, Inayath M. M. Umar, Einas Al Kuwari, Peter Coyle, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Hanan Abdul F. Rahim, Hadi M. M. Yassine, Asmaa A. A. Al Thani, Odette Chaghoury, Mohamed Ghaith Al Kuwari, Elmoubasher Farag, Roberto Bertollini, Hamad Eid Al Romaihi, Abdullatif Al Khal, Mohamed H. Al-Thani, Laith J. J. Abu-Raddad
Summary: This study investigated the seroprevalence of herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) among craft and manual workers (CMWs) in Qatar. The results showed that over 80% of CMWs are infected with HSV-1 and over 10% are infected with HSV-2. These findings highlight the need for sexual health programs to address sexually transmitted infections among the CMW population.
Article
Virology
Chun Kiat Lee, Sau Yoke Ng, Chean Nee Chai, Yu Feng Lim, Tiffany Jingyan Hu, Ogestelli Fabia Lee, Gabriel Yan
Summary: This study reports a case where unbiased metagenomic next-generation sequencing (mNGS) was successfully used as a rapid method to confirm dual genital herpes co-infection. mNGS identified specific sequences for HSV-1 or HSV-2, ruling out potential mis-genotyping by the Luminex ARIES assay. The findings suggest that mNGS can serve as a rapid and reliable alternative confirmatory method for dual genital herpes infections.
Article
Immunology
Staffan Gorander, Yoshikazu Honda-Okubo, Malin Backstrom, Jeremy Baldwin, Tomas Bergstrom, Nikolai Petrovsky, Jan-Ake Liljeqvist
Summary: The study demonstrated that EXCT4 formulated with Advax-CpG adjuvant induced a strong Th1-type immune response in mice, protected animals against HSV-2 infection, and reduced viral loads in the infected tissues.
Review
Immunology
Christine Johnston
Summary: This article discusses the management of genital herpes infection and provides recommendations based on a systematic literature review, serving as a basis for updating the treatment guidelines.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Virology
Sita Awasthi, Motoyasu Onishi, John M. Lubinski, Bernard T. Fowler, Alexis M. Naughton, Lauren M. Hook, Kevin P. Egan, Masaki Hagiwara, Seiki Shirai, Akiho Sakai, Takayuki Nakagawa, Kumiko Goto, Osamu Yoshida, Alisa J. Stephens, Grace Choi, Gary H. Cohen, Kazufumi Katayama, Harvey M. Friedman
Summary: Herpes simplex virus type 2 (HSV-2) is a major cause of genital ulcer disease and a high-risk factor for HIV transmission. The development of therapeutic vaccines is urgent to reduce the frequency of genital lesions and transmission. S-540956, a novel vaccine adjuvant, has shown great potential in reducing recurrent genital lesions and shedding of HSV-2 DNA in a guinea pig model.
Article
Virology
Nigel Bourne, Celeste A. Keith, Aaron L. Miller, Richard B. Pyles, Gary Cohen, Gregg N. Milligan
Summary: Therapeutic intravaginal immunization with HSV-2 vaccine is more effective than parenteral immunization in boosting immune responses and controlling recurrent disease and shedding.
JOURNAL OF VIROLOGY
(2023)
Article
Biotechnology & Applied Microbiology
Zhu Chen, Kaixuan Zhao, Boyu Tan, Zengrui Tong, Ziyu He, Xiaofang Luo, Lei Cai, Hanming Wang, Polly H. M. Leung, Franklin Wang-Ngai Chow, Hui Chen, Yan Deng
Summary: This paper reports a method for HSV type testing, which includes selection, design, and synthesis of specific primers, validation of amplification products by sequencing and analysis, and optimization of reaction system and PCR reaction program by orthogonal design and sensitivity testing. Results showed that this method has great potentials for HSV type testing, with a lowest detection limit of approximately 6.67 x 10(6) copies/ml, and high specificity.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Review
Immunology
Vindya Nilakshi Wijesinghe, Isra Ahmad Farouk, Nur Zawanah Zabidi, Ashwini Puniyamurti, Wee Sim Choo, Sunil Kumar Lal
Summary: Vaccine development for diseases caused by the herpes simplex virus has been challenging due to its incurable nature and widespread infection rate. Current research focuses on novel vaccine approaches, utilizing modern methods such as bioinformatics to enhance vaccine targets and formulations. This review discusses measures to enhance new vaccine development pipelines for HSV, emphasizing the potential of in silico analysis and bioinformatics in producing more effective vaccines.
EXPERT REVIEW OF VACCINES
(2021)
Article
Infectious Diseases
Mary E. Wikswo, Umesh D. Parashar, Benjamin Lopman, Rangaraj Selvarangan, Christopher J. Harrison, Parvin H. Azimi, Julie A. Boom, Leila C. Sahni, Janet A. Englund, Eileen J. Klein, Mary Allen Staat, Monica M. McNeal, Natasha Halasa, James Chappell, Geoffrey A. Weinberg, Peter G. Szilagyi, Mathew D. Esona, Michael D. Bowen, Daniel C. Payne
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY
(2020)
Article
Gastroenterology & Hepatology
Sujit K. Mohanty, Inna Lobeck, Bryan Donnelly, Phylicia Dupree, Ashley Walther, Sarah Mowery, Abigail Coots, Alexander Bondoc, Rachel M. Sheridan, Holly M. Poling, Haley Temple, Monica McNeal, Karol Sestak, Ruchi Bansal, Greg Tiao
Article
Immunology
Shannon A. Ross, Pravasini Pati, Travis L. Jensen, Johannes B. Goll, Casey E. Gelber, Amy Singh, Monica McNeal, Suresh B. Boppana, David Bernstein
JOURNAL OF INFECTIOUS DISEASES
(2020)
Article
Immunology
Mary Allen Staat, Daniel C. Payne, Natasha Halasa, Geoffrey A. Weinberg, Stephanie Donauer, Mary Wikswo, Monica McNeal, Kathryn M. Edwards, Peter G. Szilagyi, David Bernstein, Aaron T. Curns, Iddrisu Sulemana, Mathew D. Esona, Michael D. Bowen, Umesh D. Parashar
CLINICAL INFECTIOUS DISEASES
(2020)
Article
Infectious Diseases
David I. Bernstein, Jeffrey Guptill, Abdollah Naficy, Raffael Nachbagauer, Francesco Berlanda-Scorza, Jodi Feser, Patrick C. Wilson, Alicia Solorzano, Marie Van der Wielen, Emmanuel B. Walter, Randy A. Albrecht, Kristen N. Buschle, Yao-qing Chen, Carine Claeys, Michelle Dickey, Haley L. Dugan, Megan E. Ermler, Debra Freeman, Min Gao, Christopher Gast, Jenna J. Guthmiller, Rong Hai, Carole Henry, Linda Yu-Ling Lan, Monica McNeal, Anna-Karin E. Palm, Dustin G. Shaw, Christopher T. Stamper, Weina Sun, Victoria Sutton, Micah E. Tepora, Rahnuma Wahid, Heather Wenzel, Teddy John Wohlbold, Bruce L. Innis, Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
LANCET INFECTIOUS DISEASES
(2020)
Article
Immunology
Benjamin Lee, Dorothy M. Dickson, Masud Alam, Sajia Afreen, Abdul Kader, Faria Afrin, Tania Ferdousi, Christina F. Damon, Soyeon K. Gullickson, Monica M. McNeal, Daniel M. Bak, Mona Tolba, Marya P. Carmolli, Mami Taniuchi, Rashidul Haque, Beth D. Kirkpatrick
Article
Immunology
James A. Church, Bernard Chasekwa, Sandra Rukobo, Margaret Govha, Benjamin Lee, Marya P. Carmolli, Robert Ntozini, Kuda Mutasa, Monica M. McNeal, Florence D. Majo, Naume Tavengwa, Beth D. Kirkpatrick, Lawrence H. Moulton, Jean H. Humphrey, Andrew J. Prendergast
Article
Infectious Diseases
Michelle J. Groome, Lee Fairlie, Julie Morrison, Alan Fix, Anthonet Koen, Maysseb Masenya, Lisa Jose, Shabir A. Madhi, Nicola Page, Monica McNeal, Len Dally, Iksung Cho, Maureen Power, Jorge Flores, Stanley Cryz
LANCET INFECTIOUS DISEASES
(2020)
Article
Biotechnology & Applied Microbiology
Felicia Scaggs Huang, David I. Bernstein, Karen S. Slobod, Allen Portner, Toru Takimoto, Charles J. Russell, Michael Meagher, Bart G. Jones, Robert E. Sealy, Christopher Coleclough, Kristen Branum, Michelle Dickey, Kristen Buschle, Monica McNeal, Mat Makowski, Aya Nakamura, Julia L. Hurwitz
Summary: The study demonstrated that SeVRSV vaccine was well-tolerated in healthy adults with only mild to moderate reactions and no severe adverse events. Transient vaccine genome detection was observed due to preexisting immunity towards hPIV-1 and RSV in adults. Minimal antibody responses to SeV and negligible responses to RSV F were observed.
HUMAN VACCINES & IMMUNOTHERAPEUTICS
(2021)
Article
Microbiology
Kristen A. Clarkson, Robert W. Frenck, Michelle Dickey, Akamol E. Suvarnapunya, Lakshmi Chandrasekaran, Hailey P. Weerts, Christopher D. Heaney, Monica McNeal, Kate Detizio, Susan Parker, Amy Hoeper, August L. Bourgeois, Chad K. Porter, Malabi M. Venkatesan, Robert W. Kaminski
Article
Biochemistry & Molecular Biology
Raffael Nachbagauer, Jodi Feser, Abdollah Naficy, David Bernstein, Jeffrey Guptill, Emmanuel B. Walter, Franceso Berlanda-Scorza, Daniel Stadlbauer, Patrick C. Wilson, Teresa Aydillo, Mohammad Amin Behzadi, Disha Bhavsar, Carly Bliss, Christina Capuano, Juan Manuel Carreno, Veronika Chromikova, Carine Claeys, Lynda Coughlan, Alec W. Freyn, Christopher Gast, Andres Javier, Kaijun Jiang, Chiara Mariottini, Meagan McMahon, Monica McNeal, Alicia Solorzano, Shirin Strohmeier, Weina Sun, Marie Van der Wielen, Bruce L. Innis, Adolfo Garcia-Sastre, Peter Palese, Florian Krammer
Summary: New influenza virus vaccines based on chimeric hemagglutinin have been found to induce a broad, strong, durable and functional immune response targeting the conserved stalk of the hemagglutinin protein. This suggests that these chimeric hemagglutinins have the potential to be developed as universal vaccines that protect broadly against influenza viruses.
Article
Medicine, General & Internal
Sheila Isanaka, Celine Langendorf, Monica Malone McNeal, Nicole Meyer, Brian Plikaytis, Souna Garba, Nathan Sayinzoga-Makombe, Issaka Soumana, Ousmane Guindo, Rockyiath Makarimi, Marie Francoise Scherrer, Eric Adehossi, Iza Ciglenecki, Rebecca F. Grais
Summary: The study assessed the extended and strain-specific vaccine efficacy of Rotasiil in children up to 24 months of age, showing significant protection against severe rotavirus gastroenteritis in infants during the first year of life and against evolving strains over 2 years. Rotavirus vaccines like Rotasiil offer hope for reducing the burden of rotavirus disease in resource-limited settings.
Article
Medicine, General & Internal
Sheila Isanaka, Souna Garba, Brian Plikaytis, Monica Malone McNeal, Ousmane Guindo, Celine Langendorf, Eric Adehossi, Iza Ciglenecki, Rebecca F. Grais
Summary: This study examined the effect of prenatal nutritional supplementation on infant immune response to a live oral rotavirus vaccine, finding no significant impact of the type of supplementation on immunity. Variations in immune response were observed based on previous exposure to rotavirus, suggesting alternative delivery modalities may improve vaccine performance in high transmission settings.
Article
Multidisciplinary Sciences
Malabi M. Venkatesan, Cassandra Ballou, Shoshana Barnoy, Monica McNeal, Jill El-Khorazaty, Robert Frenck, Shahida Baqar
Summary: ELISA is used to evaluate mucosal immune responses by measuring antigen-specific Antibodies in Lymphocyte Supernatant instead of Antibody Secreting Cells. Two novel live oral vaccine candidates for S. sonnei, WRSs2 and WRSs3, were found to be safe, well-tolerated, and immunogenic in a dose-dependent manner. The magnitude of antigen-specific IgA- and IgG-ALS responses were measured and compared to previously described responses, showing a strong correlation and vaccine-specificity.
Article
Health Care Sciences & Services
Ardythe L. Morrow, Mary A. Staat, Emily A. DeFranco, Monica M. McNeal, Allison R. Cline, Shannon C. Conrey, Elizabeth P. Schlaudecker, Alexandra M. Piasecki, Rachel M. Burke, Liang Niu, Aron J. Hall, Michael D. Bowen, Susan I. Gerber, Gayle E. Langley, Natalie J. Thornburg, Angela P. Campbell, Jan Vinje, Umesh D. Parashar, Daniel C. Payne
Summary: The PREVAIL Cohort study aims to document the natural history of enteric and respiratory infections and immunity in children aged 0-2 years in the United States. Out of 245 mother-child pairs enrolled, 194 were compliant with the study requirements.
JMIR RESEARCH PROTOCOLS
(2021)
